Liminal BioSciences Inc.
DelistedCIK 1351172fmd_0HD47CJEY4W3AAJDG4T0QM4VMDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Jun 30, 2023, 11 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Total revenues | 22 | 25 | 1 | 1 | 1 | 0 |
| Research and development | 94 | 85 | 16 | 14 | 18 | 15 |
| Selling, general and administrative | 30 | 29 | 45 | 39 | – | – |
| Interest expense | 8 | 22 | 7 | 3 | 6 | 1 |
| Income before taxes | (136) | (259) | (151) | (49) | (45) | (29) |
| Income tax expense | (14) | (20) | (0) | (0) | 0 | (1) |
| Net income from continuing operations | (122) | (240) | (151) | (49) | (45) | (29) |
| Net income | (120) | (238) | (207) | (119) | 12 | 1 |